Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara

cafead

Administrator
Staff member
  • cafead   Dec 18, 2024 at 11:32: AM
via Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new home via a merger with fibrosis disease-focused Tvardi Therapeutics.

article source